Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 24, 2006

Primary Completion Date

December 12, 2006

Study Completion Date

December 12, 2006

Conditions
Restless Legs Syndrome
Interventions
DRUG

Ropinirole

Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.

Trial Locations (2)

6530

GSK Investigational Site, George

14050

GSK Investigational Site, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY